These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21573320)

  • 1. Wild-type p53 in cellular-transformation - a reassessment.
    Kolzau T; Deppert W
    Int J Oncol; 1993 Jul; 3(1):23-7. PubMed ID: 21573320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partially transformed T3T3 cells express high levels of mutant p53 in the 'wild-type' immunoreactive form with defective oligomerization.
    Milner J; Chan YS; Medcalf EA; Wang Y; Eckhart W
    Oncogene; 1993 Jul; 8(7):2001-8. PubMed ID: 8510941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
    Cao Y; Gao Q; Wazer DE; Band V
    Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.
    Bargonetti J; Reynisdóttir I; Friedman PN; Prives C
    Genes Dev; 1992 Oct; 6(10):1886-98. PubMed ID: 1398068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
    Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
    J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of wild-type and mutant forms of p53 protein from human tumors to a specific DNA-sequence of the first intron of the h-ras oncogene.
    Zoumpourlis V; Zachos G; Halazonetis T; Ergazaki M; Spandidos D
    Int J Oncol; 1995 Nov; 7(5):1035-41. PubMed ID: 21552928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen.
    Oren M; Levine AJ
    Proc Natl Acad Sci U S A; 1983 Jan; 80(1):56-9. PubMed ID: 6296874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
    Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
    Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type p53: tumors can't stand it.
    Kastan MB
    Cell; 2007 Mar; 128(5):837-40. PubMed ID: 17350571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the conformational phenotype of p53 and its subcellular location.
    Zerrahn J; Deppert W; Weidemann D; Patschinsky T; Richards F; Milner J
    Oncogene; 1992 Jul; 7(7):1371-81. PubMed ID: 1620550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat-shock factor 1 both positively and negatively affects cellular clonogenic growth depending on p53 status.
    Nguyen CH; Lang BJ; Chai RC; Vieusseux JL; Kouspou MM; Price JT
    Biochem J; 2013 Jun; 452(2):321-9. PubMed ID: 23510323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
    Thomas S; Reisman D
    Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant transformation of human fibroblast cell strain MSU-1.1 by N-methyl-N-nitrosourea: evidence of elimination of p53 by homologous recombination.
    Boley SE; McManus TP; Maher VM; McCormick JJ
    Cancer Res; 2000 Aug; 60(15):4105-11. PubMed ID: 10945617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7.
    McMurray HR; McCance DJ
    J Virol; 2004 Jun; 78(11):5698-706. PubMed ID: 15140967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild type human p53 is antiproliferative in SV40-transformed hamster cells.
    Mercer WE; Amin M; Sauve GJ; Appella E; Ullrich SJ; Romano JW
    Oncogene; 1990 Jul; 5(7):973-80. PubMed ID: 2165234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
    Roemer K
    Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
    Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
    Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of exogenous p53 and E6 oncoproteins in in vitro transformation by bovine papillomavirus type 4 (BPV-4): significance of the absence of an E6 ORF in the BPV-4 genome.
    Scobie L; Jackson ME; Campo MS
    J Gen Virol; 1997 Nov; 78 ( Pt 11)():3001-8. PubMed ID: 9367387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflatoxin-B exposure does not lead to p53 mutations but results in enhanced liver cancer of Hupki (human p53 knock-in) mice.
    Tong WM; Lee MK; Galendo D; Wang ZQ; Sabapathy K
    Int J Cancer; 2006 Aug; 119(4):745-9. PubMed ID: 16557586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.